Humana (NYSE:HUM) Price Target Raised to $310.00

Humana (NYSE:HUM) had its target price hoisted by Oppenheimer from $300.00 to $310.00 in a report published on Thursday morning,Benzinga reports. The brokerage currently has an outperform rating on the insurance provider’s stock.

Several other equities research analysts have also weighed in on the company. StockNews.com upgraded Humana from a “hold” rating to a “buy” rating in a research note on Monday, April 7th. Robert W. Baird upped their price target on Humana from $270.00 to $300.00 and gave the company a “neutral” rating in a research report on Tuesday, April 15th. Morgan Stanley cut their price objective on Humana from $301.00 to $285.00 and set an “equal weight” rating for the company in a report on Wednesday, February 12th. JPMorgan Chase & Co. lowered their target price on shares of Humana from $257.00 to $256.00 and set a “neutral” rating on the stock in a report on Tuesday, February 18th. Finally, Truist Financial lifted their price target on shares of Humana from $290.00 to $325.00 and gave the company a “hold” rating in a report on Friday, April 11th. Eighteen investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $287.76.

Humana Stock Performance

Shares of NYSE HUM opened at $258.21 on Thursday. The firm has a market capitalization of $31.16 billion, a price-to-earnings ratio of 25.95, a PEG ratio of 2.05 and a beta of 0.49. Humana has a one year low of $213.31 and a one year high of $406.46. The business has a fifty day simple moving average of $266.17 and a 200 day simple moving average of $270.73. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.68.

Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, April 30th. The insurance provider reported $11.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.07 by $1.51. Humana had a net margin of 1.02% and a return on equity of 11.70%. The company had revenue of $32.11 billion during the quarter, compared to analysts’ expectations of $32 billion. During the same quarter in the prior year, the company posted $7.23 EPS. The business’s revenue was up 8.4% on a year-over-year basis. Sell-side analysts expect that Humana will post 16.47 EPS for the current year.

Humana Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be paid a $0.885 dividend. This represents a $3.54 annualized dividend and a dividend yield of 1.37%. The ex-dividend date is Friday, June 27th. Humana’s dividend payout ratio (DPR) is presently 25.04%.

Institutional Investors Weigh In On Humana

A number of institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. raised its position in shares of Humana by 15.8% in the 4th quarter. Vanguard Group Inc. now owns 12,829,210 shares of the insurance provider’s stock valued at $3,254,899,000 after acquiring an additional 1,751,857 shares during the period. Dodge & Cox increased its stake in Humana by 106.7% in the fourth quarter. Dodge & Cox now owns 10,198,040 shares of the insurance provider’s stock valued at $2,587,345,000 after purchasing an additional 5,264,045 shares in the last quarter. Pzena Investment Management LLC raised its holdings in Humana by 6.1% in the first quarter. Pzena Investment Management LLC now owns 3,828,923 shares of the insurance provider’s stock worth $1,013,133,000 after purchasing an additional 219,541 shares during the period. Geode Capital Management LLC boosted its position in shares of Humana by 2.3% during the fourth quarter. Geode Capital Management LLC now owns 2,883,614 shares of the insurance provider’s stock worth $729,658,000 after purchasing an additional 63,562 shares in the last quarter. Finally, Invesco Ltd. grew its holdings in shares of Humana by 29.8% in the 4th quarter. Invesco Ltd. now owns 2,397,808 shares of the insurance provider’s stock valued at $608,348,000 after buying an additional 550,692 shares during the period. 92.38% of the stock is owned by institutional investors.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.